Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Lilly to Expand Japan Business via Alliances with Subsidiaries in Other Asian Countries
May 2, 2011
- Mitsui to Acquire Mercian's Pharma and Chemicals Business
May 2, 2011
- Drug Price Listings to Be Delayed One Month: Korosho
May 2, 2011
- OECD Japan Report Calls For Restraint in Social Security Spending
May 2, 2011
- JMA to Propose Postponing Revision of Medical, Nursing Fees
May 2, 2011
- Xyzal Ranked No. 1 in GP Market in February: RepTrack Survey
May 2, 2011
- Members of JMA Board of Trustees Disagree on Resolution to Postpone Revisions
May 2, 2011
- The Great East Japan Earthquake: MRs in the Disaster Zone
May 2, 2011
- Nat'l Consensus Needed on Drugs' Cost-effectiveness Assessment: Prof. Endo
May 2, 2011
- Wakamoto's Mid-term Management Plan Calls For Return to Black in FY2011
May 2, 2011
- Korosho to Introduce Relief Program for Families of Patients Who Die due to Anticancer Drug-related Adverse Effects
May 2, 2011
- Meiji Seika Pharma Aims at Sales of ¥200 Bil. in FY2020
May 2, 2011
- Wakamoto to Set Up JV for Generics with Taiwan Drugmaker
May 2, 2011
- HSC Approves Draft Report on Measures against Rheumatism
May 2, 2011
- Moratorium on Copayment by Quake Victims to Be Extended: Korosho
May 2, 2011
- Kyowa Kirin Completes Legal Procedures for Acquisition of ProStrakan
May 2, 2011
- Chugai's Pegasys Granted Priority Review Status for CHB
May 2, 2011
- Outgoing KEIZAI DOYUKAI Chairman Expresses Hope for His Successor from Regulation-bound Industry
May 2, 2011
- Kaken to Achieve Its Operating Profits Goal: Mizuho Securities
May 2, 2011
- Gov't Designates Eribulin as Ad-restricted Drug
May 2, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…